Published in J Exp Med on January 07, 2002
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest (2004) 2.25
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol (2009) 2.17
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2005) 1.99
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol (2010) 1.76
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A (2005) 1.76
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol (2002) 1.66
Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest (2009) 1.65
Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am (2007) 1.63
A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol (2006) 1.62
Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology (2010) 1.59
Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol (2002) 1.58
Immune evasion of natural killer cells by viruses. Curr Opin Immunol (2008) 1.51
EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem J (2003) 1.50
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol (2007) 1.44
Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology (2009) 1.40
Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol (2005) 1.40
CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol (2003) 1.38
An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37
Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology (2010) 1.37
HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. J Autoimmun (2008) 1.35
Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 1.33
Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology (2008) 1.31
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Hepatitis C virus proteins. World J Gastroenterol (2007) 1.28
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol (2003) 1.23
Modulation of natural killer cell activity by viruses. Curr Opin Microbiol (2010) 1.16
Tetraspanins in viral infections: a fundamental role in viral biology? J Virol (2005) 1.16
Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol (2010) 1.15
Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J Virol (2007) 1.15
Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol (2003) 1.09
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol (2008) 1.03
Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. J Virol (2011) 1.03
A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol (2010) 1.02
Natural killer cells suppress full cycle HCV infection of human hepatocytes. J Viral Hepat (2008) 1.02
Hepatitis C and innate immunity: recent advances. Clin Liver Dis (2008) 1.01
The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog (2013) 1.00
Liver immunology. Compr Physiol (2013) 0.99
Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J Virol (2010) 0.99
Activation of natural killer cells during microbial infections. Front Immunol (2012) 0.96
Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 0.95
Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry (2003) 0.95
Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. PLoS One (2012) 0.95
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis (2012) 0.94
Hepatitis C virus and ethanol alter antigen presentation in liver cells. World J Gastroenterol (2009) 0.94
Common threads in persistent viral infections. J Virol (2009) 0.93
CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. Hepatology (2013) 0.93
Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals. BMC Immunol (2008) 0.93
Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol (2008) 0.92
Murine viral hepatitis involves NK cell depletion associated with virus-induced apoptosis. Clin Exp Immunol (2004) 0.90
Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a. Immunology (2009) 0.89
Natural killer cell receptors and their ligands in liver diseases. Med Mol Morphol (2009) 0.88
Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology (2014) 0.88
Expression of hepatitis C virus envelope protein 2 induces apoptosis in cultured mammalian cells. World J Gastroenterol (2004) 0.87
Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology (2014) 0.86
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
Innate immune cell networking in hepatitis C virus infection. J Leukoc Biol (2014) 0.86
Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells (2014) 0.85
Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol (2012) 0.85
CD81 and hepatitis C virus (HCV) infection. Viruses (2014) 0.84
Role of host genetic factors in the outcome of hepatitis C virus infection. Viruses (2009) 0.84
The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice. Clin Vaccine Immunol (2010) 0.84
Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol (2008) 0.82
The natural killer cell response to HCV infection. Immune Netw (2013) 0.82
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med (2012) 0.82
Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis. J Virol (2013) 0.82
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
The natural killer cell cytotoxic function is modulated by HIV-1 accessory proteins. Viruses (2011) 0.81
Enhanced apoptosis of peripheral CD5-negative B lymphocytes from chronically hepatitis C virus-infected patients: reversal after antiviral treatment. J Virol (2004) 0.81
Interferon-α improves phosphoantigen-induced Vγ9Vδ2 T-cells interferon-γ production during chronic HCV infection. PLoS One (2012) 0.81
NK cells and their ability to modulate T cells during virus infections. Crit Rev Immunol (2014) 0.80
Innate immunity and hepatitis C virus infection: a microarray's view. Infect Agent Cancer (2012) 0.80
Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79
Activation of natural killer cells by hepatitis C virus particles in vitro. Clin Exp Immunol (2011) 0.79
Up-regulation of A20/ABIN1 contributes to inefficient M1 macrophage polarization during Hepatitis C virus infection. Virol J (2015) 0.79
Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection. Viral Immunol (2011) 0.79
Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B. Antimicrob Agents Chemother (2012) 0.79
A role for CD81 and hepatitis C virus in hepatoma mobility. Viruses (2014) 0.78
Altered Immune Profiles of Natural Killer Cells in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.77
Extracellular HCV-core protein induces an immature regulatory phenotype in NK cells: implications for outcome of acute infection. PLoS One (2014) 0.77
Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC. Rev Infect (2010) 0.77
Natural killer cell function and dysfunction in hepatitis C virus infection. Biomed Res Int (2014) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. Indian J Med Res (2013) 0.77
Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol (2013) 0.77
Liver infiltrating mononuclear cells in children with type 1 autoimmune hepatitis. J Clin Pathol (2006) 0.77
Adoptive transfer of splenocytes to study cell-mediated immune responses in hepatitis C infection using HCV transgenic mice. Comp Hepatol (2010) 0.76
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
Natural killer cells in hepatitis C: Current progress. World J Gastroenterol (2016) 0.76
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Biology of natural killer cells. Adv Immunol (1989) 14.77
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 13.67
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol (1999) 9.55
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science (1999) 6.21
NK cell receptors. Annu Rev Immunol (1998) 5.99
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol (1986) 5.27
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol (1998) 4.01
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul (1987) 3.45
Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity (1996) 3.33
Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature (1989) 2.91
Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. Science (1995) 2.44
Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J Exp Med (1993) 1.93
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol (2001) 1.67
Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol (1998) 1.54
Tyrosine phosphorylation provides an early and requisite signal for the activation of natural killer cell cytotoxic function. Proc Natl Acad Sci U S A (1991) 1.53
Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev (2000) 1.30
Fc receptors on natural killer cells. Curr Top Microbiol Immunol (1998) 1.25
Negative regulation of Fc epsilon RI-mediated degranulation by CD81. J Exp Med (1997) 1.18
A novel cytotoxic T lymphocyte activation assay. Optimized conditions for antigen receptor triggered granule enzyme secretion. J Immunol Methods (1987) 1.17
Management of hepatitis C: a national survey of gastroenterologists and hepatologists. Hepatology (1997) 1.04
Crosslinking CD81 results in activation of TCRgammadelta T cells. Cell Immunol (2001) 0.94
Liver biopsy interpretation in hepatitis. Part II: Histopathology and classification of acute and chronic viral hepatitis/differential diagnosis. Pathol Res Pract (1983) 0.93
NK cells and CTL: opposite sides of the same coin. Chem Immunol (1996) 0.92
Fc gamma RIII activation is different in CD16+ cytotoxic T lymphocytes and natural killer cells. Eur J Immunol (1992) 0.87
Stealth, sabotage and exploitation. Immunol Rev (1999) 0.86
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 3.35
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology (2009) 3.02
Targeting the innate immune response with improved vaccine adjuvants. Nat Med (2005) 2.63
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol (2002) 2.57
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology (2010) 2.47
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
Prospects for a vaccine against the hepatitis C virus. Nature (2005) 2.38
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest (2004) 2.25
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol (2011) 2.11
CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med (2003) 2.01
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol (2005) 1.94
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol (2007) 1.78
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A (2005) 1.76
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol (2013) 1.68
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov (2003) 1.60
Phylogeny of the SARS coronavirus. Science (2003) 1.56
Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol (2004) 1.51
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology (2009) 1.48
Long-term results of drug-eluting balloon angioplasty for treatment of refractory recurrent carotid in-stent restenosis. J Endovasc Ther (2014) 1.47
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood (2013) 1.42
Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol (2013) 1.41
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology (2011) 1.40
Epidemiology and management of neuropsychiatric disorders in Behçet's syndrome. CNS Drugs (2015) 1.39
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood (2008) 1.28
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol (2008) 1.27
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol (2005) 1.27
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol (2003) 1.25
Safety of MF59 adjuvant. Vaccine (2008) 1.25
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine (2007) 1.24
Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol (2009) 1.24
Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem (2004) 1.24
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog (2012) 1.23
Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J Immunol (2012) 1.22
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology (2005) 1.22
Evaluating the efficiency of isotope transmission for improved panel design and a comparison of the detection sensitivities of mass cytometer instruments. Cytometry A (2015) 1.21
In vivo identification of novel STAT5 target genes. Nucleic Acids Res (2008) 1.19
Combining affinity purification by ADP-ribose-binding macro domains with mass spectrometry to define the mammalian ADP-ribosyl proteome. Proc Natl Acad Sci U S A (2009) 1.18
Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. World J Gastroenterol (2009) 1.17
Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol (2005) 1.16
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis (2013) 1.16
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog (2013) 1.15
MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res (2009) 1.14
Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol (2004) 1.12
Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol (2003) 1.12
The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J Exp Med (2014) 1.09
Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. Immunol Rev (2013) 1.09
Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol (2009) 1.09
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol (2006) 1.09
Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology (2010) 1.08
Physiological relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins. FEBS J (2005) 1.06
Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) (2011) 1.06
Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood (2004) 1.06
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) (2011) 1.04
CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. J Exp Med (2010) 1.03
Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther (2003) 1.03
Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol (2012) 1.02
Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism. J Immunol (2010) 1.02
A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther (2006) 1.01
Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab (2009) 1.00
T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur J Immunol (2003) 0.99
Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology (2002) 0.99
Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism (2009) 0.98
Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform (2015) 0.98
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int (2012) 0.98
Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling. J Biol Chem (2004) 0.96